Abstract
A novel prodrug rationally designed to function as a tyrosinase substrate has been synthesised to allow targeted treatment of malignant melanoma. This agent has been evaluated for tyrosinase-mediated drug release, and has been shown to act in the desired manner. Furthermore, differential cytotoxicity has been demonstrated in cell lines which express tyrosinase and those which do not.
| Original language | English |
|---|---|
| Pages (from-to) | 1775-80 |
| Number of pages | 6 |
| Journal | Bioorganic and Medicinal Chemistry |
| Volume | 7 |
| Issue number | 9 |
| Publication status | Published - Sept 1999 |
Keywords
- Animals
- CHO Cells
- Cricetinae
- Magnetic Resonance Spectroscopy
- Melanocytes
- Melanoma
- Monophenol Monooxygenase
- Prodrugs
- Tumor Cells, Cultured